Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.46 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23620931 | 0.85 | GPR119 (0.48) | GPR119MMP13 | |
| SCHEMBL30307823 | 0.84 | GPR119 (0.50) | GPR119STSMMP13 | |
| SCHEMBL20502297 | 0.84 | GPR119 (0.50) | GPR119STSMMP13 | |
| SCHEMBL23620946 | 0.84 | GPR119 (0.50) | GPR119STSMMP13 | |
| SCHEMBL23620932 | 0.80 | GPR119 (0.47) | GPR119STSCA12CA1CA2 | |
| SCHEMBL30307812 | 0.80 | GPR119 (0.47) | GPR119STSCA12CA1CA2 | |
| SCHEMBL20502393 | 0.78 | CA2 (0.49) | GPR119STSCA12CA1CA2 | |
| SCHEMBL23620977 | 0.77 | GPR119 (0.52) | GPR119CA2 | |
| SCHEMBL4773698 | 0.75 | MEN1 (0.51) | GPR119STSMMP13 | |
| SCHEMBL27200525 | 0.74 | GPR119 (0.50) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | GPR119 3054/4885STS 3566/4885MMP13 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.